Protocol merck 318-00: A double-blind, placebo-controlled, randomized, parallel, clinical trial to study the effect of losartan potassium on endothelial dysfunction and insulin resistance in obese patients with impaired fasting glucose

Trial Profile

Protocol merck 318-00: A double-blind, placebo-controlled, randomized, parallel, clinical trial to study the effect of losartan potassium on endothelial dysfunction and insulin resistance in obese patients with impaired fasting glucose

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2013

At a glance

  • Drugs Losartan (Primary)
  • Indications Essential hypertension; Glucose intolerance; Insulin resistance
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Jul 2012 Actual patient number changed from 153 to 53 as reported by ClinicalTrials.gov.
    • 02 Feb 2009 Actual patient numbers (153) added as reported by ClinicalTrials.gov.
    • 02 Feb 2009 Actual end date changed from Jul 2008 to Dec 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top